Pfizer: Best Trading Momentum Since 2021 And 6% Yield

Simfo/E+ via Getty Images Pfizer (NYSE:PFE)(NEOE:PFE:CA) has been a losing investment idea for several years, really since peak pandemic demand was reached for its leading COVID vaccines and antiviral prescription drugs. I have mentioned the stock several times as a strong income/yield proposition starting in 2022, with better than sector average valuations. Yet, the share quote has responded with flat to even lower pricing. My last bullish article was posted in December here. Finally, some stronger tra ...